RemeGen Co., Ltd. (HKG:9995)
Hong Kong · Delayed Price · Currency is HKD 81.25
+0.90 (1.12%)
Feb 3, 2026, 4:08 PM HKT
RemeGen Market Cap
RemeGen has a market cap or net worth of 55.53 billion as of February 3, 2026. Its market cap has increased by 388.60% in one year.
Market Cap
55.53B
Enterprise Value
56.62B
Revenue
2.43B
Ranking
n/a
PE Ratio
n/a
Stock Price
81.25
Market Cap Chart
Since November 9, 2020, RemeGen's market cap has increased from 33.39B to 55.53B, an increase of 66.30%. That is a compound annual growth rate of 10.20%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Feb 2, 2026 | 55.53B | 22.85% |
| Dec 31, 2025 | 45.20B | 222.75% |
| Dec 31, 2024 | 14.00B | -55.02% |
| Dec 29, 2023 | 31.13B | -25.43% |
| Dec 30, 2022 | 41.75B | 9.42% |
| Dec 31, 2021 | 38.16B | -18.00% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Nov 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Innovent Biologics | 140.68B |
| Sino Biopharmaceutical | 118.70B |
| Akeso | 101.69B |
| Sichuan Kelun-Biotech Biopharmaceutical | 96.87B |
| 3SBio | 58.20B |
| Shanghai Junshi Biosciences | 36.42B |
| TransThera Sciences (Nanjing) | 32.98B |
| Biocytogen Pharmaceuticals (Beijing) | 32.27B |